AC Immune’s (NASDAQ:ACIU) lock-up period will end on Wednesday, March 22nd. AC Immune had issued 6,000,000 shares in its public offering on September 23rd. The total size of the offering was $66,000,000 based on an initial share price of $11.00. After the end of AC Immune’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
A number of equities research analysts recently weighed in on ACIU shares. Leerink Swann restated an “outperform” rating on shares of AC Immune in a report on Saturday, November 26th. Zacks Investment Research lowered shares of AC Immune from a “buy” rating to a “hold” rating in a report on Wednesday, February 8th. Credit Suisse Group AG restated an “outperform” rating and issued a $18.00 target price on shares of AC Immune in a report on Tuesday, December 13th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $25.00 target price on shares of AC Immune in a report on Tuesday, December 13th.
Your IP Address:
Shares of AC Immune (NASDAQ:ACIU) opened at 11.55 on Tuesday. AC Immune has a 12-month low of $10.36 and a 12-month high of $19.97. The company has a 50 day moving average of $12.20 and a 200-day moving average of $13.42. The firm’s market cap is $572.22 million.
Large investors have recently made changes to their positions in the company. FMR LLC raised its stake in shares of AC Immune by 13.4% in the fourth quarter. FMR LLC now owns 3,637,402 shares of the company’s stock worth $46,344,000 after buying an additional 428,815 shares during the period. Artal Group S.A. raised its stake in shares of AC Immune by 66.7% in the fourth quarter. Artal Group S.A. now owns 250,000 shares of the company’s stock worth $3,245,000 after buying an additional 100,000 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of AC Immune during the fourth quarter worth about $457,000. 14.39% of the stock is currently owned by institutional investors and hedge funds.
About AC Immune
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Receive News & Ratings for AC Immune Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune Ltd and related companies with MarketBeat.com's FREE daily email newsletter.